Seventeen-year follow-up of the prospective randomized Nordic CIS study: BCG monotherapy versus alternating therapy with mitomycin C and BCG in patients with carcinoma in situ of the urinary bladder

Scandinavian Journal of Urology

Volumn 50, Issue 5, 2016, Pages 360-368

  Kaasinen, Eero ^a   Wijkström, Hans ^b   Rintala, Erkki ^c   Mestad, Oddvar ^d   Jahnson, Staffan ^e   Malmström, Per Uno ^f  

^a HYVINKÄÄ HOSPITAL   (Finland)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^d UNIVERSITY OF STAVANGER   (Norway)

^e LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

BCG; carcinoma in situ; combination therapy; immunotherapy; instillation therapy; long term efficacy; mitomycin C; randomized controlled trial; urinary bladder

Indexed keywords

ANTINEOPLASTIC AGENT; BCG VACCINE; MITOMYCIN; ANTINEOPLASTIC ANTIBIOTIC; IMMUNOLOGICAL ADJUVANT;

AGED; ARTICLE; BLADDER CARCINOMA; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CARCINOMA IN SITU; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CYSTECTOMY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; NEPHROURETERECTOMY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; TUMOR GROWTH; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; TIME FACTOR; URINARY BLADDER NEOPLASMS;

ADJUVANTS, IMMUNOLOGIC; AGED; ANTIBIOTICS, ANTINEOPLASTIC; BCG VACCINE; CARCINOMA IN SITU; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MITOMYCIN; PROSPECTIVE STUDIES; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84981711266     PISSN: 21681805     EISSN: 21681813     Source Type: Journal    
DOI: 10.1080/21681805.2016.1210672     Document Type: Article

References (30)

1. J.Ferlay, I.Soerjomataram, R.Dikshit, S.Eser, C.Mathers, M.Rebelo,. Cancer incidence and mortality worldwide:sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359–86.
2. U.Norming, C.R.Nyman, B.Tribukait Comparative histopathology and deoxyribonucleic acid flow cytometry of random mucosal biopsies in untreated bladder carcinoma. J Urol 1991;145:1164–8.
3. H.Wolf, P.Rosenkilde Olsen, A.Fischer, K.Højgaard. Urothelial atypia concomitant with primary bladder tumour. Incidence in a consecutive series of 500 unselected patients. Scand J Urol Nephrol 1987;21:33–8.
4. D.Lamm Carcinoma in situ. Urol Clin North Am 1992;19:499–508.
5. F.Liedberg, O.Hagberg, S.Holmäng, A.Hosseini Aliabad, G.Jancke, B.Ljungberg,. Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden:a population-based follow-up study. Scand J Urol 2015;49:290–5.
6. M.Babjuk, M.Burger, R.Zigeuner, S.F.Shariat, B.W.van Rhijn, E.Compérat,. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder:update 2013. Eur Urol 2013;64:639–53.
7. E.Kaasinen, H.Wijkström, P.U.Malmström, S.Hellsten, M.Duchek, Nordic Urothelial Cancer Group,. Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder:a Nordic study. Eur Urol 2003;43:637–45.
8. T.Hemdan, R.Johansson, S.Jahnson, P.Hellström, I.Tasdemir, Members of the Urothelial Cancer Group of the Nordic Association of Urology. 5-Year outcome of a randomized prospective study comparing bacillus Calmette-Guérin with epirubicin and interferon-α2b in patients with T1 bladder cancer. J Urol 2014;191:1244–9.
9. E.Solsona, R.Madero, V.Chantada, J.M.Fernandez, J.A.Zabala, J.A.Portillo,. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) in more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients:final outcome of CUETO 93009, a randomized prospective trial. Eur Urol 2015;67:508–16.
10. D.C.Chade, S.F.Shariat, G.Godoy, C.J.Savage, A.M.Cronin, B.H.Bochner,. Clinical outcomes of primary bladder carcinoma in situ in a contemporary series. J Urol 2010;184:74–80.
11. D.C.Chade, S.F.Shariat, A.Adamy, B.H.Bochner, S.M.Donat, H.W.Herr,. Clinical outcome of primary versus secondary bladder carcinoma in situ. J Urol 2010;184:464–9.
12. T.de Reijke, K.Kurth, R.Sylvester, R.R.Hall, M.Brausi, K.van de Beek,. Bacillus Calmette–Guérin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder:results of a European organization for the research and treatment of cancer – genito-urinary group phase III trial (30906). J Urol 2005;173:405–9.
13. G.Jakse, R.Hall, A.Bono, W.Höltl, P.Carpentier, J.Spaander,. Intravesical BCG in patients with carcinoma in situ of the urinary bladder:long-term results of EORTC GU group phase II protocol 30861. Eur Urol 2001;40:144–50.
14. J.Martinez-Pineiro, L.Martinez-Pineiro, E.Solsona, R.H.Rodríguez, J.M.Gómez, M.G.Martín,. Has a 3-fold decreased dose of bacillus Calmette–Guerin the same efficacy against recurrences and progression of T1G3 and TIS bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005;174:1242–7.
15. D.L.Lamm, B.A.Blumenstein, J.D.Crissman, J.E.Montie, J.E.Gottesman, B.A.Lowe,. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder:a randomized Southwest Oncology Group Study. J Urol 2000;163:1124–9.
16. A.Losa, R.Hurle, A.Lembo Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder:long-term results. J Urol 2000;163:68–71.
17. J.Oddens, M.Brausi, R.Sylvester, A.Bono, C.van de Beek, G.van Andel,. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder:one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 2013;63:462–72.
18. R.J.Sylvester, M.A.Brausi, W.J.Kirkels, W.Hoeltl F.Calais Da Silva, EORTC Genito-Urinary Tract Cancer Group,. Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guérin, and bacillus Calmette-Guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57:766–73.
19. R.Järvinen, E.Kaasinen, E.Rintala, FinnBladder Group. Long-term results of mitomycin C versus alternating mitomycin C and bacillus Calmette-Guérin instillation therapy of patients with carcinoma in situ of the bladder:a subgroup analysis of the prospective, randomized FinnBladder 2 study with a 17-year follow-up. Scand J Urol Nephrol 2012;46:411–17.
20. R.Järvinen, T.Marttila, E.Kaasinen, E.Rintala, S.Aaltomaa, FinnBladder Group,. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations:prospective randomised FinnBladder-4 study. Eur Urol 2015;68:611–17.
21. J.L.Au, R.A.Badalament, M.G.Wientjes, D.C.Young, J.A.Warner, P.L.Venema,. Methods to improve efficacy of intravesical mitomycin C:results of a randomized phase III trial. J Natl Cancer Inst 2001;93:597–604.
22. S.M.Di Stasi, A.Giannantoni, R.L.Stephen, G.Capelli, P.Navarra, R.Massoud,. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer:a prospective randomized study. J Urol 2003;170:777–82.
23. S.M.Di Stasi, A.Giannantoni, A.Giurioli, M.Valenti, G.Zampa, L.Storti,. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer:a randomised controlled trial. Lancet Oncol 2006;7:43–51.
24. P.Andius, O.Damm, S.Holmäng. Prognostic factors in patients with carcinoma in situ treated with intravesical bacille Calmette-Guérin. Scand J Urol Nephrol 2004;38:285–90.
25. K.Zieger, K.Jensen. Long-term risk of progression of carcinoma in situ of the bladder and impact of bacille Calmette-Guérin immunotherapy on the outcome. Scand J Urol Nephrol 2011;45:411–18.
26. M.S.Cookson, H.W.Herr, Z.F.Zhang, S.Soloway, P.C.Sogani, W.R.Fair The treated natural history of high risk superficial bladder cancer:15-year outcome. J Urol 1997;158:62–7.
27. M.Sant, C.Allemani, M.Santaquilani, A.Knijn, F.Marchesi, R.Capocaccia, EUROCARE Working Group. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009;45:931–91.
28. J.R.Oddens, R.J.Sylvester, M.A.Brausi, W.J.Kirkels, C.van de Beek, G.van Andel,. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer:results from EORTC genito-urinary group study 30911. Eur Urol 2014;66:694–701.
29. H.W.Herr, M.S.Cookson, S.M.Soloway Upper tract tumors in patients with primary bladder cancer followed for 15 years. J Urol 1996;156:1286–7.
30. J.Palou, R.J.Sylvester, O.R.Faba, R.Parada, J.A.Peña, F.Algaba,. Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin. Eur Urol 2012;62:118–25.